Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
247<br />
* Six states have no standards related to the compounding of sterile pharmaceutical<br />
products.<br />
* Eight states have standards thatfail to address compounding of sterile inhalati<strong>on</strong><br />
soluti<strong>on</strong>s.<br />
Inhalati<strong>on</strong> soluti<strong>on</strong>s must be sterile and are currently manufactured by compoundinfg<br />
pharmacies <strong>on</strong> a massive scale. Eight states have addressed sterile compounding of<br />
injectable products without addressing inhalati<strong>on</strong> soluti<strong>on</strong>s. See Ala. Admin. Code r.<br />
680-x-2.19 (2007); Cal. Code Regs. tit. 16, § 1751.02, et seq. (2007); D.C. Mun. Regs.<br />
Tit. 22, § 1923 (2007); Idaho Admin. Code r. 27.01.01.178 (2007); III. Admin. Code tit.<br />
68, § 1330.99 (2007); Kan. Admin. Regs. § 68-13-1 (2007); 201 Ky. Admin. Regs. 2:076<br />
(2007); N.D. Admin. Code 61-06-01-01, et seq. (2007).<br />
* Most states have no requirements specific to high-risk compounding.<br />
Many inhalati<strong>on</strong> drugs, as well as other drugs that must be sterile, are being compounded<br />
from n<strong>on</strong>sterile ingredients. The USP defines such compounding as "high-risk"<br />
compounding. Because such compounding is very difficult and poses special risks for<br />
patients, the USP provides stricter standards for high-risk compounding in USP .<br />
Most states that provide standards for sterile compounding fail to address the special<br />
c<strong>on</strong>cerns posed by high-risk compounding. See Ariz. Admin. Code § 4-23-670 (2007);<br />
Alaska Divisi<strong>on</strong> of Corporati<strong>on</strong>s, Business and Professi<strong>on</strong>al Licensing, Alaska Pharmacy<br />
Statutes and Regulati<strong>on</strong>s (2007), at Appendix A and Appendix C; Iowa Admin Code r.<br />
657-8.30 (2007); La. Admin. Code tit. 46, §§ 2535(2), 2537; 02-392-018 Me. Code R. §<br />
flet tn7 AA - xAA r',.4- 0,. -_ n 'I I 1901 Al.<br />
flff'00<br />
1, et seq. {200?); Md. C ode V ;M. 10... 6ouU.aUUU - 6800.8008 U2007);<br />
M<strong>on</strong>t. Admin. R. 24.174.1121 (2007); Nev. Admin. Code §§ 639.525(5), 639.684 (2007);<br />
N.H. Code R. Ph. 404.01, et seq. (2007); N.J. Admin. Code § 13:39-11.1, et seq. (2007);<br />
N.C. Admin. Code 46.2800, et seq. (2007); Okla. Admin. Code § 535:15-19-1, etseq.<br />
(2007); Or. Admin. R. 855-041-0063 (2007); 14-130-001 R.I. Code R. § 19 (2007); S.C.<br />
Code Ann. § 40-43-88 (2007); S.D. Admin. R. 20:51:26:01, et seq. (2007); Tenn. Comp.<br />
R. & Regs. 11 40-7-.0 1, et seq.; 04-030-230 Vt. Code R. part G (2007); Wash. Admin.<br />
Code §§ 246-878-040(1), 246-878-050; W. Va. Code R. §§ 15-1-15.2.3, 15-1-16 (2007);<br />
Wis. Admin. Code Pharm. Examin. Bd., § 15.01, etseq. (2007); 024-059-013 Wyo. Code<br />
R. § 10 (2007). Only eight states with sterile compounding standards address high-risk<br />
compounding. See 070-02-0001 Ark. Code R. (2007); Ga. Comp. R. & Regs. 480-11-<br />
0.02, Ga. Comp. R. & Regs. 480-11-.04 (2007); 3 Colo. Code Regs. § 719-1 (2007); 10-<br />
522-001 Del. Code Regs. § X (2007); Fla. Admin. Code Ann. r. 64B16-28.820 (2007);<br />
Mo. Code Regs. Ann. tit. 20, §§ 2220-2.200, 2220-2.020 (H) (2007); Ohio Admin. Code<br />
4729:19-04,4729:9-25 (2007); 22 Tex. Admin. Code § 291.26 (2007); 18 Va. Admin.<br />
Code § 110-20-411, et seq. (2007).